North America Sterilization Equipment Market Outlook, 2031

Market Drivers

• Escalating rates of hospital-acquired infections (HAIs) and surgical volume: High patient admission rates across hospitals and ambulatory surgical centers (ASCs) in the U.S. and Canada directly drive the demand for continuous, high-volume sterilization. HAIs such as central line-associated bloodstream infections and surgical site infections impose significant financial penalties on healthcare providers through regulatory mandates and extended patient stays. Combined with an aging demographic requiring more surgical interventions, healthcare facilities are forced to continuously invest in advanced autoclaves, reprocessors, and automated washer-disinfectors to guarantee strict sterility standards.
• Expanding biopharmaceutical manufacturing and complex drug delivery: North America remains a global hub for biopharmaceutical research and manufacturing. The surge in biologic therapies, cell and gene therapies, and mRNA-based vaccines requires ultra-clean production environments and specialized processing equipment. Because active pharmaceutical ingredients (APIs) and specialized containment vessels cannot tolerate biological contamination, contract manufacturing organizations (CMOs) and pharma giants are heavily investing in industrial-grade steam, radiation, and isolator sterilization units to ensure safety and regulatory compliance.

Market Challenges

• Regulatory overhaul and environmental phase-out of ethylene oxide (EtO): Ethylene Oxide (EtO) has historically served as the primary gaseous sterilant for heat- and moisture-sensitive single-use medical devices. However, stringent regulations from the U.S. Environmental Protection Agency (EPA) regarding EtO emissions and occupational air exposure are placing intense pressure on commercial sterilization plants. Facilities face potential closures, costly emission-abatement retrofits, and prolonged clearance cycles, causing supply chain bottlenecks for medical device manufacturers reliant on off-site processing.
• High capital expenditure and operational costs for infrastructure upgrades: Advanced medical sterilization equipment such as vaporized hydrogen peroxide (VHP) chambers, automated endoscope reprocessors (AERs), and radiation sterilizers demands substantial initial capital investment. Beyond procurement, ongoing operational costs include specialized utility installation, routine chemical validation, high power consumption, and specialized technical labor. Small-to-midsize hospitals and outpatient clinics frequently struggle with capital allocations, leading to delayed equipment replacements and reliance on third-party service providers.

Market Trends

• Accelerated transition toward low-temperature and alternative sterilization technologies: Due to the rise of complex, heat-sensitive medical electronics, endoscopes, and polymer-based implants, traditional steam autoclaving is no longer suitable for all equipment. As a result, the market is shifting toward low-temperature methods like Vaporized Hydrogen Hydrogen Peroxide (VHP), Nitrogen Dioxide NO2, and Supercritical Carbon Dioxide CO2. These alternative modalities offer shorter cycle times, zero toxic residue, and enhanced compatibility with delicate components, making them the preferred choice for both hospitals and device manufacturers seeking alternatives to EtO.
• Integration of IoT, automation, and real-time traceability software: Modern Central Sterile Supply Departments (CSSDs) are moving away from manual logging and paper tracking. Sterilization equipment is increasingly equipped with Internet of Things (IoT) connectivity, automated sensor monitoring, and tracking software. These systems automatically capture parameters like temperature, exposure time, pressure, and sterilant concentration, linking every sterilized tray directly to a specific patient or surgical theater. This digital shift reduces human error, provides immediate audit readiness, and enables predictive maintenance for healthcare equipment.